SGK1 and Other metabolic disease: Accordingly, SGK1 signalling would be expected to increase in metabolically active organs such as liver, muscle and fat where the content of LDs largely increases under physiological adaptations and metabolic diseases (obesity, hepatic steatosis, lipodistrophy and diabetes mellitus type 2).42, 43, 44